July 6, 2010

Dear Nuclear Medicine Professional,

Covidien has successfully obtained additional quantities of molybdenum 99 (Mo 99) from our reactor partners for the month of July, enabling us to produce technetium 99m (Tc 99m) generators on two additional dates this month (July 9 and 16) at our U.S. facility. Updated projection calendars* for Tc 99m generators in the Americas are shown below, with daily views for both July and August. These supply estimates include the return of the High Flux Reactor (HFR) in mid August per the latest reports from NRG1.

Separately, we are also pleased to announce U.S. Food and Drug Administration approval for manufacture of Tc 99m generators produced with Mo 99 from the Czech Rez reactor. We continue to use Tc 99m generators produced from Rez-derived Mo 99 in part of Europe as well. As we have throughout the shortage, Covidien fairly distributes all available Mo 99 to all global regions.

Increased thallium Tl 201 for those procedures where it can be a clinically appropriate substitute continues to be available. You are encouraged to interact frequently with your Covidien representative to ensure your thallium needs are known.

We are committed to frequent communication when new updates are available. Please visit us at www.covidien.com/Mo99supply, where you can learn how to download a convenient new application or “app” for iPhones®, iPads® and BlackBerrys®, providing you with easy access to Covidien’s most current Mo 99 calendars and communications.

Sincerely,

Elaine E. Haynes, RPh
Vice President & General Manager, U.S. Commercial Operations, Imaging

---

2 Registered trademarks of Apple Inc.
3 Registered trademark of Research in Motion Inc.